Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025)
Adma Biologics (ADMA) reported Liabilities from Discontinued Operations of 2647000.0 for Q4 2025.
Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025) Analysis & Trends
Adma Biologics has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 2647000.0 in Q4 2025.
- For the quarter ending Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 2647000.0; the trailing twelve-month figure through Dec 2025 stood at 2647000.0 (changed N/A YoY), and the FY2025 full-year result was 2647000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2025 stood at 2647000.0.
- The five-year high for Liabilities from Discontinued Operations was 2647000.0 in Q4 2025, with the low at 2647000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.65 Mn |
| Dec 31, 2025 | 2.65 Mn |